This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Carcinoma in situ of other and unspecified sites기타 및 상세불명 부위의 제자리암 (기타부위제자리암)

📋 Contents and key points
A. Classification codesICD-10: D09 | D09.0 Carcinoma in situ of bladder | D09.1 Carcinoma in situ of other urinary organs | D09.2 Carcinoma in situ of eye (conjunctival and corneal CIN) | D09.3 Carcinoma in situ of thyroid and other endocrine glands | D09.7 Carcinoma in situ of other specified sites | D09.9 Carcinoma in situ, unspecified site | Special Copayment Reduction V193 (5% copayment, for 5 years from the registration date)
B. SynonymsBladder carcinoma in situ (bladder CIS, urothelial CIS), high-grade squamous intraepithelial carcinoma of the bladder, conjunctival intraepithelial neoplasia, corneal intraepithelial neoplasia, carcinoma in situ of the ureter and urethra, Bowen's disease (non-cutaneous sites), transitional cell CIS of the upper urinary tract
C. Adult onsetVery high — bladder CIS mainly in male smokers aged 50 and over; conjunctival CIN in people in their 50s–70s with high UV exposure; all D09 lesions have onset in late adulthood
Contents 1. History · 2. Causes · 3. Genetics · 4. Epidemiology · 5. Pathophysiology · 6. Symptoms · 7. Signs · 8. Screening · 9. Diagnosis · 10. Treatment · 11. Prognosis · 12. Prevention · 13. References
1. History summaryEisenberg (1952) first described bladder CIS; introduction of urinary cytology (Papanicolaou); concept of conjunctival CIN in the 1960s; development of intravesical BCG instillation therapy (1976).
2. Causes summaryBladder: smoking (50% of risk), aromatic amines, radiation, cyclophosphamide; conjunctiva: UV, HPV, immunosuppression; thyroid: radiation.
3. Genetics summaryBladder CIS: FGFR3 (low-grade pathway), TP53, TERT promoter mutations; conjunctival CIN: KRAS, TP53, UV signature; 9p21 deletion.
4. Epidemiology summaryBladder CIS accounts for about 10% of all bladder cancers; about 5,500 bladder cancer cases per year in Korea; conjunctival CIN has high incidence in Africa and Australia.
5. Pathophysiology summaryCarcinogens → DNA damage in bladder transitional cells → TP53 and TERT mutations → full-thickness atypia (CIS); bladder CIS follows the high-grade pathway (TP53 first).
6. Symptoms summaryBladder CIS: hematuria, irritative voiding symptoms (frequency, urgency, dysuria); conjunctival CIN: redness, foreign body sensation; thyroid CIS: asymptomatic.
7. Signs summaryRed, velvety flat lesions on cystoscopy; high-grade abnormality on urine cytology; slit-lamp findings of conjunctival ocular surface intraepithelial neoplasia; fluorescence cystoscopy.
8. Screening summaryUrine cytology and cystoscopy follow-up for high-risk groups for occupational bladder cancer; regular cystoscopy after bladder cancer treatment; conjunctival CIN: eye examination for those at high risk from UV exposure.
9. Diagnosis summaryCystoscopy + biopsy (bladder CIS); urine cytology; FISH (UroVysion); conjunctival excisional biopsy; ALA/HAL photodynamic-assisted cystoscopy.
10. Treatment summaryIntravesical BCG/MMC instillation (standard for bladder CIS); endoscopic resection and ESD (gastrointestinal CIS); RFA (Barrett's high-grade dysplasia); conjunctival excision ± mitomycin C.
11. Prognosis summaryComplete response rate to BCG for bladder CIS 60–80%; 5-year bladder cancer progression rate 10–20%; local recurrence rate after excision of conjunctival CIN 30–40%.
12. Prevention summarySmoking cessation (key to prevention of bladder CIS); blocking occupational carcinogens; UV protection (conjunctival CIN); adequate fluid intake.

1. History

Among carcinomas in situ of other sites (D09), the most clinically important lesion is bladder CIS. In 1952, Eisenberg, Bluestein and Weinstein described proliferation of high-grade dysplastic cells in the bladder lining without invasive cancer and without basement membrane invasion, establishing the concept of bladder carcinoma in situ. They emphasized that bladder CIS is both an important precursor lesion of invasive bladder cancer and an independent lesion.

Urinary cytology applies to the urinary tract the technique Papanicolaou developed in the 1940s along with cervical cytology, and it was introduced clinically in the 1950s–60s as a noninvasive means of detecting high-grade dysplasia and CIS of the bladder. The sensitivity of cytology for bladder CIS is about 40–60%, lower than the lesion detection rate of cystoscopy, but it is useful for detecting minute CIS lesions not visible on cystoscopy. In 1976, Morales et al. first reported that intravesical BCG (Bacillus Calmette-Guérin) instillation is effective against non-muscle-invasive bladder cancer (especially CIS), and intravesical BCG instillation was subsequently established as the standard immunotherapy for bladder CIS. The concept of conjunctival intraepithelial neoplasia (conjunctival CIN) developed from the 1960s, and the roles of HPV and UV were later demonstrated.

2. Causes

Causes of bladder CIS (D09.0): smoking is the strongest risk factor, accounting for about 50% of bladder cancer cases. Aromatic amines and polycyclic aromatic hydrocarbons (PAH) in tobacco smoke are excreted in the urine and come into direct contact with the bladder mucosa, causing DNA damage. The bladder cancer risk of smokers is 4–7 times higher than that of nonsmokers. Occupational carcinogens: risk is high among workers in the rubber, dye, printing and leather industries who are occupationally exposed to aromatic amines (2-naphthylamine, benzidine), aniline dyes and 4-aminobiphenyl. Cyclophosphamide: this alkylating agent used as an anticancer drug is metabolized to acrolein, a bladder toxin, raising the risk of bladder CIS. Radiation therapy: increased risk of bladder CIS/cancer after pelvic radiation therapy (cervical cancer, rectal cancer, etc.). Chronic cystitis and irritation: long-term indwelling catheters, bladder stones and chronic cystitis are also risk factors. Conjunctival CIN (D09.2): UV exposure, HPV infection and immunosuppression are the main causes.

3. Genetics

Bladder cancer (transitional cell carcinoma) arises through two main genetic pathways. High-grade pathway (CIS-related): TP53 mutation (about 60% of bladder CIS) is the key early event. 9q deletion (TSC1, DBC1), RB1 loss and CDKN2A deletion accompany it. TERT promoter mutations (C228T, C250T) are found in about 60–80% of bladder cancers and contribute to cellular immortalization through telomerase reactivation. ERBB2 (HER2) amplification is found in some high-grade bladder cancers. Low-grade pathway (papillary tumors): characterized by FGFR3 mutation (about 70% of low-grade papillary bladder cancers), which is mutually exclusive with HRAS mutation. Bladder CIS is associated with the high-grade pathway rather than the low-grade papillary pathway.

FISH analysis of bladder CIS: copy number changes of RREB1 (6p25), CCND1 (11q13), MYB (6q23) and CEP6 are used as a diagnostic aid (UroVysion FISH kit). Genetics of conjunctival CIN: UV signature (C→T transitions), KRAS and TP53 mutations; 9p21 deletion (CDKN2A). In HPV-related conjunctival CIN, E6/E7 suppress TP53/RB1.

4. General epidemiology

Bladder CIS (D09.0) accounts for about 10% of all non-muscle-invasive bladder cancers (NMIBC) and occurs alone or together with high-grade papillary bladder cancer. Annual new bladder cancer cases in Korea number about 5,500 (2022), with men affected 3–4 times more than women. Bladder CIS is classified as occurring alone (primary CIS), accompanying other bladder cancer (concomitant CIS), or recurring after treatment (secondary CIS). Isolated CIS shows the highest risk of invasive progression. Conjunctival CIN (D09.2) has a high incidence in regions with intense UV radiation, such as East Africa (Kenya, etc.), Australia and tropical South America (0.13–1.9 per 100,000 population). It is relatively rare in Korea. Thyroid CIS (D09.3) is very rare and is observed more often in people with a history of radiation exposure.

5. Pathophysiology

Pathophysiology of bladder CIS: the bladder transitional epithelium (urothelium) is continuously exposed to urine containing carcinogens (tobacco metabolites, occupational carcinogens). These carcinogens damage the DNA of urothelial cells, and mutations in TP53 and the TERT promoter in particular occur as early events. TP53 loss suppresses the DNA damage response and apoptosis, allowing atypical cell clones to survive. TERT reactivation promotes cellular immortalization. These changes develop into bladder CIS, in which high-grade dysplastic cells proliferate throughout the full thickness of the bladder mucosa while the basement membrane is still intact.

Bladder CIS represents an extreme form of field cancerization; the entire bladder mucosa is in a molecularly altered state (field defect), characterized by multifocality and recurrence. When basement membrane invasion occurs, it progresses to T1 (invasion of the lamina propria) or T2 (muscle invasion) invasive bladder cancer. The rate of progression from bladder CIS to muscle-invasive bladder cancer (MIBC) is high (about 50% within 5 years without treatment), which is why aggressive treatment is needed.

6. Symptoms

Bladder CIS (D09.0): the symptoms of bladder CIS are difficult to distinguish from those of high-grade transitional cell carcinoma, but there are some characteristic symptoms. Lower urinary tract symptoms (LUTS): irritative voiding symptoms — frequency (pollakiuria), urgency and dysuria — are the most common symptoms of bladder CIS. This is because CIS cells stimulate sensory receptors in the bladder mucosa, and it is often mistaken for cystitis. Hematuria: gross hematuria or microscopic hematuria can occur in bladder CIS, but is more common in accompanying papillary bladder cancer than in CIS itself. Isolated bladder CIS frequently presents with irritative voiding symptoms alone without gross hematuria, which can delay diagnosis. Conjunctival CIN (D09.2): there may be eye redness, foreign body sensation and changes in vision, but asymptomatic cases are also common. Reduced vision occurs with corneal involvement.

7. Signs

Cystoscopic findings: on cystoscopy, bladder CIS appears as erythematous velvety flat lesions, mucosal irregularity and friability (tendency to contact bleeding). Because it may appear normal on standard cystoscopy (invisible CIS), multiple random biopsies are needed when urine cytology is abnormal but cystoscopy is normal. Photodynamic diagnosis cystoscopy (PDD): after intravesical instillation of ALA (5-aminolevulinic acid) or HAL (hexaminolevulinate), CIS mucosa appears as red fluorescence under blue-violet light, improving the sensitivity of CIS detection by about 20–30% compared with standard cystoscopy. Urinary cytology: high-grade dysplastic transitional cells are found in bladder washings or spontaneously voided urine. The cytological sensitivity for bladder CIS is about 40–60%. In conjunctival CIN, slit-lamp examination shows white or salmon-colored thickened plaque-like lesions of the conjunctival epithelium.

8. Screening

Population screening for bladder CIS is currently not recommended. However, regular examination is important in the following high-risk groups. Workers exposed to occupational carcinogens: some countries recommend urine cytology and cystoscopy every 2 years for workers exposed to aromatic amines in the dye, rubber, leather and printing industries. Korean occupational health guidelines also designate occupations subject to special health examinations for bladder cancer. Follow-up after bladder cancer treatment: after treatment of bladder CIS or high-grade non-muscle-invasive bladder cancer, regular cystoscopy (initially at 3 months, then every 6 months, then annually) and urine cytology are performed. Evaluation of hematuria: gross hematuria or recurrent microscopic hematuria in adults requires cystoscopy and urine cytology to rule out bladder cancer (including CIS). Conjunctival CIN: regular eye examinations are recommended for residents of areas with strong UV exposure and for immunosuppressed patients.

9. Diagnosis

Cystoscopy + biopsy: bladder CIS is confirmed by biopsy of suspicious lesions under cystoscopic guidance. Even if cystoscopy is normal, random biopsies (four quadrants of the bladder + posterior urethra) are performed if urine cytology is abnormal. Histopathology: high-grade nuclear atypia throughout the full thickness of the transitional epithelium (irregular nuclear shape, abnormal mitoses, increased nuclear/cytoplasmic ratio), basement membrane intact. Loss of cellular cohesion is characteristic. Urinary cytology: Papanicolaou cytology of spontaneously voided urine (second morning urine recommended) or bladder washings. High-grade dysplastic transitional cells are found in bladder CIS. The Bethesda urinary cytology reporting system (2016 Paris System for Reporting Urinary Cytology) is used. Fluorescence cystoscopy (PDD cystoscopy): fluorescence is observed by cystoscopy with a blue-violet light source 1 hour after intravesical instillation of HAL (Hexvix). The CIS detection rate is significantly improved compared with standard cystoscopy. FISH (UroVysion): analysis of chromosomal copy number of RREB1, CCND1, MYB and CEP6 in urothelial cells. Useful as a diagnostic aid when cytology interpretation is indeterminate. Conjunctival CIN: slit-lamp examination + histopathology of conjunctival excisional biopsy.

10. Treatment

Treatment of bladder CIS (D09.0): bladder CIS is classified as high-grade non-muscle-invasive bladder cancer (NMIBC) and requires aggressive treatment. Intravesical BCG (Bacillus Calmette-Guérin) instillation is the standard first-line treatment. BCG activates an immune response in the bladder mucosa to eliminate CIS cells. Induction therapy: once weekly for 6 weeks (1 course). When a complete response is achieved, maintenance therapy is given for 1–3 years (3 weekly BCG instillations repeated at 3, 6, 12, 18, 24, 30 and 36 months; Lamm maintenance schedule). BCG complete response rate: achieved in about 60–80%. In BCG-unresponsive CIS: intravesical mitomycin C (MMC) or gemcitabine instillation; or radical cystectomy is considered. Recently, new immunotherapies such as intravesical nadalipin/pebrutumab (intravesical pembrolizumab instillation) are being studied in BCG-unresponsive bladder CIS. Treatment of conjunctival CIN: wide local excision + alcohol epitheliectomy or cryotherapy. Mitomycin C eye drops (MMC 0.04%) are effective in recurrent or extensive conjunctival CIN.

11. Prognosis

Bladder CIS (D09.0) is the lesion with the highest risk of progression among high-grade non-muscle-invasive bladder cancers. After a complete response to BCG: 5-year recurrence-free survival about 60–70%, 5-year progression rate to muscle-invasive bladder cancer about 10–20%. If there is no complete response to BCG or the disease is BCG-unresponsive, radical cystectomy is considered. Left untreated: the rate of progression of isolated bladder CIS to muscle-invasive cancer is very high, about 50% at 5 years and about 65% at 10 years, so aggressive treatment is essential. After radical cystectomy: the 5-year cancer-specific survival of radical cystectomy for bladder CIS is about 80–90%. Cystoscopic follow-up: after completion of BCG therapy, cystoscopy + urine cytology every 3 months (1–2 years), then every 6 months. Conjunctival CIN: the local recurrence rate after excision is about 30–40%, but because the prognosis worsens if it progresses to invasive ocular squamous cell carcinoma, regular ophthalmologic follow-up is needed.

12. Prevention

Smoking cessation: the most effective means of preventing bladder CIS/bladder cancer. Bladder cancer risk decreases after quitting smoking, but it takes decades to return to the level of nonsmokers. Therefore early smoking cessation is important. Blocking exposure to occupational carcinogens: at workplaces handling bladder carcinogens such as aromatic amines and aniline dyes, environmental monitoring, use of personal protective equipment and strengthened ventilation systems are essential. Adequate fluid intake: epidemiological data indicate that drinking 1.5–2L or more of fluid per day dilutes the concentration of carcinogens in contact with the bladder mucosa and shortens exposure time, reducing bladder cancer risk by about 20–30%. When administering cyclophosphamide: mesna is co-administered to block acrolein-induced bladder toxicity. Prevention of conjunctival CIN: wearing UV-blocking sunglasses (UV 400 protection), regular eye examinations in immunosuppressed patients. During radiation therapy: bladder exposure dose is minimized by minimizing the pelvic radiation field and by radiation shielding.


13. References

  1. Eisenberg RB, Roth RB, Schweinsberg MH. Bladder tumors and associated proliferative vesical lesions. J Urol. 1960;84:544-550.
  2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180-183.
  3. Lamm DL, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129.
  4. Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. Eur Urol. 2006;49(3):466-477.
  5. Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241.
  6. Karnwal A, et al. Carcinoma in situ of the bladder: Is there a difference in efficacy between various BCG strains? Cancers. 2024;16(3):599.
  7. Babjuk M, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ). Eur Urol. 2022;81(1):75-94.
  8. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 3.2024. National Comprehensive Cancer Network, 2024.
  9. Gichuhi S, Macharia E, Kabiru J, et al. Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya. JAMA Ophthalmol. 2016;134(12):1365-1372.
  10. Korean Urological Association. Standard Clinical Practice Recommendations for Urologic Cancer: Bladder Cancer. Korean Urological Association, 2023.